Evidence map›Paper›PMID 18431474›Full record

ArticlePloS one2008

Serum antibodies to Porphyromonas gingivalis chaperone HtpG predict health in periodontitis susceptible patients.

Charles E Shelburne, P Sandra Shelburne, Vishnu M Dhople, Domenica G Sweier, William V Giannobile, Janet S Kinney, Wilson A Coulter, Brian H Mullally, Dennis E Lopatin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. T and B Cells in Periodontal Disease: New Functions in A Complex Scenario.International journal of molecular sciences · 2019
    Review
  5. Frontiers in microbiology · 2017
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Host response mechanisms in periodontal diseases.Journal of applied oral science : revista FOB
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Charles E ShelburneDepartment of Biologic and Materials Sciences, The University of Michigan School of Dentistry, Ann Arbor, Michigan, United States of America. ceshelbu@umich.edu
P Sandra Shelburne
Vishnu M Dhople
Domenica G Sweier
William V Giannobile
Janet S Kinney
Wilson A Coulter
Brian H Mullally
Dennis E Lopatin
Michigan United · USUniversity of Michigan–Ann Arbor · US

Funding

ZINC GLUCONATE GLYCINE LOZENGES &VITAMIN C EFFECTS ON COMMON COLDM01RR000042 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RUBENFIRE, MELVYN · 1985 to 2007
$40.8M
Integrated Microfluidic System for Oral DiagnosticsU01DE014961 · NIDCR · SANDIA CORP-SANDIA NATIONAL LABORATORIES · PI SINGH, ANUP K · 2002 to 2005
$4.2M
Immunodominant Stress Proteins of Porphyromonas gingivalisR01DE011117 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOPATIN, DENNIS E · 1996 to 2010
$2.4M
NCRR NIH HHS M01 RR000042NCRR NIH HHS M01-RR000042NIDCR NIH HHS DE11117NIDCR NIH HHS R01 DE011117NIDCR NIH HHS U01 DE014961NIDCR NIH HHS U01-DE-14961
6 · The paper itself

Abstract

backgroundChaperones are ubiquitous conserved proteins critical in stabilization of new proteins, repair/removal of defective proteins and immunodominant antigens in innate and adaptive immunity. Periodontal disease is a chronic inflammatory infection associated with infection by Porphyromonas gingivalis that culminates in the destruction of the supporting structures of the teeth. We previously reported studies of serum antibodies reactive with the human chaperone Hsp90 in gingivitis, a reversible form of gingival disease confined to the oral soft tissues. In those studies, antibodies were at their highest levels in subjects with the best oral health. We hypothesized that antibodies to the HSP90 homologue of P. gingivalis (HtpG) might be associated with protection/resistance against destructive periodontitis. METHODOLOGY/PRINCIPAL

findingsELISA assays using cloned HtpG and peptide antigens confirmed gingivitis subjects colonized with P. gingivalis had higher serum levels of anti-HtpG and, concomitantly, lower levels of attachment loss. Additionally, serum antibody levels to P. gingivalis HtpG protein were higher in healthy subjects compared to patients with either chronic or aggressive periodontitis. We found a negative association between tooth attachment loss and anti-P. gingivalis HtpG (p = 0.043) but not anti-Fusobacterium nucleatum (an oral opportunistic commensal) HtpG levels. Furthermore, response to periodontal therapy was more successful in subjects having higher levels of anti-P. gingivalis HtpG before treatment (p = 0.018). There was no similar relationship to anti-F. nucleatum HtpG levels. Similar results were obtained when these experiments were repeated with a synthetic peptide of a region of P. gingivalis HtpG. CONCLUSIONS/SIGNIFICANCE: OUR RESULTS SUGGEST: 1) anti-P. gingivalis HtpG antibodies are protective and therefore predict health periodontitis-susceptable patients; 2) may augment the host defence to periodontitis and 3) a unique peptide of P. gingivalis HtpG offers significant potential as an effective diagnostic target and vaccine candidate. These results are compatible with a novel immune control mechanism unrelated to direct binding of bacteria.

Indexed as

HealthSerumAdultAmino Acid SequenceAntibodies, BacterialAntibody FormationAntigens, BacterialBacterial ProteinsCluster AnalysisColony Count, MicrobialDental PlaqueDisease SusceptibilityFemaleFusobacterium nucleatumHSP90 Heat-Shock ProteinsHumansAntibodies, BacterialAntigens, BacterialBacterial ProteinsHSP90 Heat-Shock ProteinsHtpG protein, bacteriaImmunoglobulin GMolecular ChaperonesPeptides

Identifiers

PMID18431474
PMCPMC2291562
OpenAlexW2081499120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.